Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q1 2025 · 10-Q
Revenue$0.00$0.00— vs Q1 2024 Net Income-$216.83K-$216.83KN/M vs Q1 2024 EPS Diluted$0.00$0.00— vs Q1 2024 Operating Income-$216,831N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
ended Apr 30, 2024 · filed Apr 2, 2026 · 702 d after period end